

+

<i>Attorney Docket No.</i>	PC11013A
<i>First Inventor</i>	John P. Mueller
<i>Title</i>	HarA Polypeptides and Nucleic Acids, and Related Methods and Uses Thereof
<i>Express Mail Label No.</i>	EL625571291US

(Only for new nonapplications under 37C.F.R. §1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Commissioner for Patents
Box Patent Application
Washington, DC 20231

- | | |
|--|--|
| <p>1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)</p> <p>2. <input type="checkbox"/> Applicant claims small entity status
See 37 CFR 1.27</p> <p>3. <input checked="" type="checkbox"/> Specification [Total Pages <input]<br="" type="text" value="51"/>(preferred arrangement set forth below)</p> <ul style="list-style-type: none"> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R&D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure <p>4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total sheets <input]<="" p="" type="text" value="8"/> <p>5. <input checked="" type="checkbox"/> Oath or Declaration [Total pages <input]<="" p="" type="text" value="1"/> <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 18 completed) <ul style="list-style-type: none"> i. <input type="checkbox"/> DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). <p>6. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p> </p></p> | <p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or computer Program (Appendix)</p> <p>8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)</p> <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> Computer Readable Copy (CRF) b. Specification Sequence Listing on: <ul style="list-style-type: none"> i. <input type="checkbox"/> CD-ROM or CD-R (2 copies) ii. <input checked="" type="checkbox"/> Paper c. <input checked="" type="checkbox"/> Statement verifying identity of above copies |
|--|--|

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))

10. ☐ 37 CFR 3.73(b) Statement ☒ Power of Attorney
(when there is an assignee)

11. ☐ English Translation Document (if applicable)

12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations

13. ☐ Preliminary Amendment

14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.

17. ☐ Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____ / _____

Prior application information: Examiner _____ Group/Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☐ Correspondence address below



23913

Name _____

Address

City

State

Zip Code

Country

Telephone

Fax

NAME (Print/type)

Jeffrey N. Myers

Registration No. (Attorney/Agent)

41.213

Signature

Date _____

January 30, 2002

**FEE TRANSMITTAL
For FY 2001***Patent Fees are subject to annual Revision***Total Amount of Payment** (\$1076.00)**Complete if Known**

Application Number

Filing Date

January 30, 2002

First Named Inventor

John P. Mueller

Examiner Name

Group/Art Unit

Attorney Docket No.

PC11013A

METHOD OF PAYMENT1. ☒The commissioner is hereby authorized to charge
Indicated fees and credit any over payments to:Deposit
Account
Number

16-1445

Deposit
Account
Name

Pfizer Inc

☒Charge Any Additional Fee Required
Under 37 CFR 1.16 and 1.17☐

Applicant claims small entity status.

☐

See 37 CFR 1.27

☐

Payment Enclosed:

☐

Check

☐ Credit card☐ Money Order☐ Other**FEE CALCULATION****BASIC FILING FEE**

Large Entity Fee Code	Fee (\$)	Small Entity Fee Code	Fee (\$)	Fee Description	Fee Paid
101	740	201	355	Utility filing fee	740
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Filing fee	
SUBTOTAL (1) (\$)					740

2. EXTRA CLAIM FEES

	Extra Claims		Fee from below		Fee Paid
Total Claims	17	-20**=	0	X	=
Independent Claims	7*	-3**=	4	X	84 = 336
Multiple Dependent					=
Large Entity	Small Entity				
Fee Code	Fee	Fee code	Fee	Fee Description	
103	18	203	9	Claims in excess of 20	
102	84	202	42	Independent claims in excess of 3	
104	280	204	140	Multiple dependent claim, if not paid	
109	80	209	42	**Reissue independent claims over original patent	
110	18	210	9	**Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)				(\$)	336.00

** or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Fee Code	Large Entity Fee (\$)	Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late fee or oath	
127	50	227	25	Surcharge-late filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279	355	Request for Continued Examination(RCE)	
169	900	169	900	Request for expedited examination of a design application	


Other (specify) _____

*Reduced by Basic Filing Fee Paid

Subtotal (3)

0

SUBMITTED BY*Complete (if applicable)*

Type or Printed Name	Jeffrey N. Myers	Registration No. (Attorney/Agent)	41,213	Telephone	212-733-5061
Signature				Date	January 30, 2002

CERTIFICATE OF MAILING EXPRESS MAIL

PFIZER DOCKET NUMBER: PC11013A

APPLICATION NUMBER: Unassigned

TITLE: HarA Polypeptides and Nucleic Acids, and Related Methods and Uses
Thereof


APPLICANTS: John P. Mueller, et al.

Express Mail mailing label number EL625571291US

Date of Deposit: January 30, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" service under 37 C.F.R.1.10 on the date indicated above and is addressed to Commissioner for Patents, Box Patent Application, Washington, DC 20231.

By:


(Signature of person mailing)

Vilma Pizarro

(Typed or printed name of person)

Pfizer Inc.
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5612

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mueller, et al. :

APPLICATION NO.: Not Yet Known : Examiner:

FILING DATE: January 30, 2002 : Group Art Unit:

TITLE: HAR A POLYPEPTIDES AND NUCLEIC :
ACIDS, AND RELATED METHODS AND
USES THEREOF

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Statement under 37 C.F.R. 1.825

Pursuant to 37 C.F.R. 1.825 (b), attorney for applicants states that the copy of the Sequence Listing in Computer Readable Form is the same as the substitute paper copy of the Sequence Listing submitted herewith. Pursuant to 37 C.F.R. 1.825 (d), attorney for applicants states further, that the substitute Sequence Listing data is identical to that originally filed.

Date: January 30, 2002



Jeffrey N. Myers
Attorney for Applicant(s)
Reg. No. 41,213

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5612
(212) 733-5061

20020130